TPI 1100
There is no current medical therapy for COPD that affects prognosis. Inflammation is present within the airways of patients with COPD and is characterized by an increase in neutrophils, macrophages, and CD8+ T lymphocytes. This inflammation is different from that in asthma. It is believed that blocking the inflammatory cells that are present or the mediators that are released could prevent the progression of COPD
TPI 1100
Topigen is applying its unique multitargeted approach to the development of truly effective therapeutic products for the treatment of COPD with the objective of halting the progression of the disease. TPI 1100 is being developed to be specific, with broader effects than current therapies and has the potential of improving the prognosis of this chronic, debilitating and deadly disease.
http://www.topigen.com/en/science/chronic.html
There is no current medical therapy for COPD that affects prognosis. Inflammation is present within the airways of patients with COPD and is characterized by an increase in neutrophils, macrophages, and CD8+ T lymphocytes. This inflammation is different from that in asthma. It is believed that blocking the inflammatory cells that are present or the mediators that are released could prevent the progression of COPD
TPI 1100
Topigen is applying its unique multitargeted approach to the development of truly effective therapeutic products for the treatment of COPD with the objective of halting the progression of the disease. TPI 1100 is being developed to be specific, with broader effects than current therapies and has the potential of improving the prognosis of this chronic, debilitating and deadly disease.
http://www.topigen.com/en/science/chronic.html